FDA has accepted Karyopharm Therapeutics Inc.’s supplemental New Drug Application seeking approval for Xpovio—its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
